CFTR Activator Compounds for Constipation and Dry Eye Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for safe and effective treatments for constipation and dry eye disorders, as current therapies have limited efficacy and do not address the underlying issues effectively.
Innovation Solution
Development of compounds that activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to treat constipation, dry eye, and other disorders by administering effective amounts of specific compounds to subjects in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current laxatives and chloride channel activators are used to treat constipation, then therapeutic options are available, but efficacy is variable and unimpressive
Solution Approach 1:
The patent modifies the chemical structure of lubiprostone by replacing the terminal carboxylic acid group with various alternative groups (amides, esters, ketones, nitriles, etc.) to create analogs with potentially improved efficacy. This structural parameter change aims to optimize the compound's ability to activate chloride channels while reducing variability in therapeutic response.
Solution Approach 2:
The invention creates a series of hybrid compounds that combine the core lubiprostone structure with different terminal groups, effectively creating composite molecular structures. These composite analogs are designed to retain the beneficial chloride channel activation properties while improving overall therapeutic reliability and consistency.
2Reliability
If topical cyclosporine is used to treat dry eye, then ocular surface inflammation is reduced, but symptoms are not eliminated in most patients
Solution Approach 1:
The patent describes compounds that can simultaneously address multiple aspects of dry eye pathology - not only reducing inflammation like cyclosporine but also directly stimulating chloride channel activity to enhance tear production and ocular surface hydration. This multi-functional approach aims to eliminate symptoms more completely.
Solution Approach 2:
By developing small molecule CFTR activators with optimized pharmacological properties, the invention seeks to change the therapeutic parameter from purely anti-inflammatory action to a combined anti-inflammatory and tear-stimulating effect, thereby improving overall symptom relief reliability.
3Adaptability or versatility
If CFTR activators are developed to treat both constipation and dry eye, then therapeutic versatility is improved, but treatment safety must be maintained
Solution Approach 1:
The patent describes a series of CFTR activator compounds that can treat multiple conditions (constipation, dry eye, other CFTR-related disorders) through a single mechanism of action. This universal therapeutic approach improves versatility while maintaining a consistent safety profile across different indications, as the compounds act through the same validated CFTR activation pathway.
Data Source
AI summary
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.